22nd Oct 2019 14:54
(Alliance News) - Creo Medical Group PLC announced the full commercial launch of its Speedboat device on Tuesday and the first showcase of three other products in the same platform.
Shares in the medical device maker were up 6.4% at 183.00 pence in London on Tuesday.
Speedboat is the first among Creo's gastrointestinal medical devices to be cleared for use and
is intended for use in flexible endoscopy, where it lets doctors perform surgical procedures such as removing cancerous and pre-cancerous growths.
According to Creo, Speedboat "combines bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation".
The launch was announced at the United European Gastroenterology Week Congress in Barcelona, where Creo is exhibiting and showcasing its CROMA Advanced Energy platform. These are its products enabling "a wide variety of procedures" to be done during endoscopy instead of in an operating theatre.
CROMA devices being showcased include the Haemostasis Device, which "is the only non-stick haemostasis device in any sphere of therapy", and the Resection Device - a bipolar radiofrequency scissors device for laprosopic procedures. In addition, Creo showcased its Narrow Probe ablation needle, "the smallest microwave ablation device in any sphere" with potential in managing gastrointestinal diseases.
Chief Executive Craig Gulliford said: "The full commercial launch of the Speedboat device, coupled with the opportunity to show-case the wider suite of products at this key event, is another important step for the company. In addition to the profiling of our technology in the exhibition area, we will also be using the time together with our distribution partners throughout Europe to outline the initial roll out plans for the wider portfolio and use this fantastic opportunity to build further excitement and momentum as we head into 2020."
By Anna Farley; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Creo Medical